MHRA-101547-PIP01-24

Key Facts

Active Substance
Active Substance:
  • IgG-like T cell engager binding to DLL3 and CD3
Invented Name
Not available at present
PIP Number MHRA-101547-PIP01-24
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
  • Treatment of small cell lung carcinoma
  • Treatment of neuroendocrine carcinoma, (excluding neuroblastoma)
Route(s) of administration
Route(s) of administration:
  • Parenteral use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):IgG-like T cell engager binding to DLL3 and CD3.pdf
Published Date 29/11/2024